Antineutrophil cytoplasmic antibody-positive conversion and microscopic polyangiitis development in patients with idiopathic pulmonary fibrosis

BMJ Open Respiratory Research

Volumn 2, Issue 1, 2015, Pages 1-9

  Kagiyama, Naho ^a   Takayanagi, Noboru ^a   Kanauchi, Tetsu ^a   Ishiguro, Takashi ^a   Yanagisawa, Tsutomu ^a   Sugita, Yutaka ^a  

^a Saitama Cardiovascular and Respiratory Center ^*  (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; CREATININE; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; RHEUMATOID FACTOR;

ACUTE RESPIRATORY FAILURE; ADULT; AGED; ARTICLE; CLINICAL EVALUATION; COHORT ANALYSIS; CORTICOSTEROID THERAPY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; FIBROSING ALVEOLITIS; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GASTROINTESTINAL HEMORRHAGE; GLOMERULONEPHRITIS; HUMAN; LUNG CANCER; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MICROSCOPIC POLYANGIITIS; MONONEUROPATHY; MORTALITY; PNEUMONIA; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PURPURIC RASH; RETROSPECTIVE STUDY; SEROCONVERSION; SURVIVAL;

EID: 84942811019     PISSN: None     EISSN: 20524439     Source Type: Journal    
DOI: 10.1136/bmjresp-2014-000058     Document Type: Article

References (35)

1. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92.
2. Watts R, Lane S, Hanslik T, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007;66:222-7.
3. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised international chapel hill consensus conference nomenclature of Vasculitides. Arthritis Rheum 2013;65:1-11.
4. Gómez-Puerta JA, Hernández-Rodriguez J, López-Soto A, et al. Antineutrophil cytoplasmic antibody-associated vasculitides and respiratory disease. Chest 2009;136:1101-11.
5. Brown KK. Pulmonary vasculitis. Proc Am Thorac Soc 2006;3:48-57.
6. Nada AK, Torres VE, Ryu JH, et al. Pulmonary fibrosis as an unusual clinical manifestation of a pulmonary-renal vasculitis in elderly patients. Mayo Clin Proc 1990;65:847-56.
7. Becker-Merok A, Nossent JC, Ritland N. Fibrosing alveolitis predating microscopic polyangiitis. Scand J Rheumatol 1999;28:254-6.
8. Hiromura K, Nojima Y, Kitahara T, et al. Four cases of anti-myeloperoxidase antibody-related rapidly progressive glomerulonephritis during the course of idiopathic pulmonary fibrosis. Clin Nephrol 2000;53:384-9.
9. Mansi IA, Opran A, Sondhi D, et al. Microscopic polyangiitis presenting as idiopathic pulmonary fibrosis: is anti-neutrophilic cytoplasmic antibody testing indicated? Am J Med Sci 2001;321:201-2.
10. Eschun GM, Mink SN, Sharma S. Pulmonary interstitial fibrosis as a presenting manifestation in perinuclear antineutrophilic cytoplasmic antibody microscopic polyangiitis. Chest 2003;123:297-301.
11. Birnbaum J, Danoff S, Askin FB, et al. Microscopic polyangiitis presenting as a "pulmonary-muscle" syndrome: is subclinical alveolar hemorrhage the mechanism of pulmonary fibrosis? Arthritis Rheum 2007;56:2065-71.
12. Bhanji A, Karim M. Pulmonary fibrosis-an uncommon manifestation of anti-myeloperoxidase-positive systemic vasculitis? NDT Plus 2010;3:351-3.
13. Shields O, Shah A, Mann B. Pyrexia of unknown origin and pulmonary fibrosis as a presentation of MPO-ANCA associated vasculitis. BMJ Case Rep 2011;2011. doi:10.1136/bcr.01.2011.3692
14. Eleftheriou D, Katsenos S, Zorbas S, et al. Pulmonary fibrosis presenting as an early manifestation of microscopic polyangiitis. Monaldi Arch Chest Dis 2012;77:141-4.
15. Arulkumaran N, Periselneris N, Gaskin G, et al. Interstitial lung disease and ANCA-associated vasculitis: a retrospective observational cohort study. Rheumatology (Oxford) 2011;50:2035-43.
16. Hervier B, Pagnoux C, Agard C, et al. Pulmonary fibrosis associated with ANCA-positive vasculitides. Retrospective study of 12 cases and review of the literature. Ann Rheum Dis 2009;68:404-7.
17. Tzelepis GE, Kokosi M, Tzioufas A, et al. Prevalence and outcome of pulmonary fibrosis in microscopic polyangiitis. Eur Resp J 2010;36:116-21.
18. Gal AA, Salinas FF, Staton GW Jr. The clinical and pathological spectrum of antineutrophil cytoplasmic autoantibody-related pulmonary disease. A comparison between perinuclear and cytoplasmic antineutrophil cytoplasmic autoantibodies. Arch Pathol Lab Med 1994;118:1209-14.
19. Gaudin PB, Askin FB, Falk RJ, et al. The pathologic spectrum of pulmonary lesions in patients with anti-neutrophil cytoplasmic autoantibodies specific for anti-proteinase 3 and anti-myeloperoxidase. Am J Clin Pathol 1995;104:7-16.
20. Ando Y, Okada F, Matsumoto S, et al. Thoracic manifestation of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA)-related disease. CT findings in 51 patients. J Comput Assist Tomogr 2004;28:710-16.
21. Chung MP, Yi CA, Lee HY, et al. Imaging of pulmonary vasculitis. Radiology 2010;255:322-41.
22. Foulon G, Delaval P, Valeyre D, et al. ANCA-associated lung fibrosis: analysis of 17 patients. Respir Med 2008;102: 1392-8.
23. Ando M, Miyazaki E, Ishii T, et al. Incidence of myeloperoxidase anti-neutrophil cytoplasmic antibody positivity and microscopic polyangitis in the course of idiopathic pulmonary fibrosis. Respir Med 2013;107:608-15.
24. Nozu T, Kondo M, Suzuki K, et al. A comparison of the clinical features of ANCA-positive and ANCA-negative idiopathic pulmonary fibrosis patients. Respiration 2009;77:407-15.
25. Tanaka T, Otani K, Egashira R, et al. Interstitial pneumonia associated with MPO-ANCA: clinicopathological features of nine patients. Respir Med 2012;106:1765-70.
26. Yamada H. ANCA: associated lung fibrosis. Semin Respir Crit Care Med 2011;32:322-7.
27. Homma S, Matsushita H, Nakata K. Pulmonary fibrosis in myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitides. Respirology 2004;9:190-6.
28. Poletti V, Ravaglia C, Buccioli M, et al. Idiopathic pulmonary fibrosis: diagnosis and prognostic evaluation. Respiration 2013;86:5-12.
29. Guilpain P, Chéreau C, Goulvestre C, et al. The oxidation induced by antimyeloperoxidase antibodies triggers fibrosis in microscopic polyangiitis. Eur Respir J 2011;37:1503-13.
30. Tsiveriotis K, Tsirogianni A, Pipi E, et al. Antineutrophil cytoplasmic antibodies testing in a large cohort of unselected greek patients. Autoimmune Dis 2011;2011:626495.
31. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;161:646-64.
32. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
33. Kang BH, Park JK, Roh JH, et al. Clinical significance of serum autoantibodies in idiopathic interstitial pneumonia. J Korean Med Sci 2013;28:731-7.
34. Guillevin L, Durand-Gasselin B, Cevallos R, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999;42:421-30.
35. Raghu G, Anstrom KJ, King TE Jr, et al. Idiopathic Pulmonary Fibrosis Clinical Research Network, Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012;366:1968-77.